2026 Annual Meeting | C36 - Updates in Diagnostics and Management of Small Fiber Neuropathy

Date Saturday 04/18/26

Time 02:30 PM - 04:30 PM CDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Lawrence A. Zeidman, MD, FAAN

Topic(s) Neuromuscular and Clinical Neurophysiology (EMG)

Learning Objectives Participants should become familiar with small fiber neuropathy (SFN) (patho)physiology and its presentation; SFN-specific questionnaires for use in clinic and for the trial; the workup for SFN and indications for EMG, skin biopsies, autonomic studies, corneal confluence microscopy, and laboratory studies; novel immune SFN biomarkers; dthe role of genetic therapies and other novel anti-amyloid treatments in hereditary SFN; the role of immunotherapy in immune SFN- steroids, IVIG, Plasmapheresis; if there is a role to Rituxan, Efgartigimod, or other agents in Immune SFN; results of multiple open label studies supporting the use of IVIG in immune SFN, and some randomized trials; and ongoing randomized controlled Immune SFN-IVIG study background and rationale, inclusion/exclusion criteria, and schedule of events

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice, Quality Improvement

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Medical Student, Coordinator

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
02:30 PM - 02:50 PM CDT	Speaker	Introduction and Overview of Small Fiber Neuropathy (SFN) and Diagnostic Testing Lawrence A. Zeidman, MD, FAAN
02:50 PM - 03:15 PM CDT	Speaker	Update and Overview of Skin Biopsies, SFN Diagnostic Schematics, and Links to Fibromyalgia and Pain Syndromes Todd D. Levine, MD
03:15 PM - 03:30 PM CDT	Speaker	Update in Hereditary SFN Management - eg, TTR Amyloid, Fabry's Disease, Sodium Channelopathies Amanda C. Chan, MD
03:30 PM - 03:45 PM CDT	Speaker	Updates in SFN Inflammatory Markers and Pathophysiology Amanda C. Chan, MD
03:45 PM - 04:15 PM CDT	Speaker	Update in Inflammatory SFN Treatment - Controversies and Ongoing Trials Lawrence A. Zeidman, MD, FAAN
04:15 PM - 04:30 PM CDT	Q&A	Questions and Answers Lawrence A. Zeidman, MD, FAAN, Todd D. Levine, MD, Amanda C. Chan, MD

Faculty Disclosures
Lawrence A. Zeidman, MD, FAAN	Dr. Zeidman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Zeidman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Johnson. Dr. Zeidman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Zeidman has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Smith Blake Hill LLC. The institution of Dr. Zeidman has received research support from Octapharma. Dr. Zeidman has received publishing royalties from a publication relating to health care.
Todd D. Levine, MD	Dr. Levine has received personal compensation for serving as an employee of CND life sciences . Dr. Levine has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Nufactor. Dr. Levine has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for PNA. Dr. Levine has stock in CND Life Sciences. Dr. Levine has stock in Corinthian reference lab.
Amanda C. Chan, MD	Dr. Chan has nothing to disclose.

��ɫ��

��ɫ��